Etesevimab

• UNSPSC Description:

  Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody[1].

• Target Antigen:

  Angiotensin-converting Enzyme (ACE); SARS-CoV

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/etesevimab.html

• Purity:

  98.76

• Solubility:

  H2O

• Smiles:

  [Etesevimab]

• References & Citations:

  [1]Wu X, et al. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0035021.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 4

• CAS Number:

  2423948-94-9